Autoimmune Disease

117

Pipeline Programs↗

116

Active Trials↗

54

Companies Involved↗

Autoimmune Disease is a highly competitive landscape with 117 programs across 54 companies. The most active players are Nanjing Bioheng Biotech Co., Ltd., Nanjing Legend Biotech Co., Grit Biotechnology. 5 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

77/100

Pipeline Velocity

71/100

Mech. Concentration

9/100

Completion Rate

69/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Nanjing Bioheng Biotech Co., Ltd.

3 programs

Nanjing Legend Biotech Co.

3 programs

Grit Biotechnology

2 programs

Fate Therapeutics

2 programs

China Immunotech (Beijing) Biotechnology Co., Ltd.

1 program

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

1 program

Analysis

Modality Breakdown

114programs

Small molecule5346%

Cell therapy4035%

Monoclonal antibody1211%

Vaccine44%

Protein / enzyme22%

RNA therapy22%

Radiopharmaceutical11%

Modality classified for 100% of 151 pipeline programs.

Analysis

Trial Status

152

clinical trials

Recruiting72 · 47%

Not yet recruiting34 · 22%

Completed20 · 13%

Unknown status7 · 5%

Active, not recruiting6 · 4%

Terminated4 · 3%

Other9 · 6%

Clinical Trials

Trial Activity

152 trials

Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases

Recruiting·JJuventas Cell Therapy Ltd.·Phase 1·NCT06316791·24 enrolled

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

Recruiting·CChina Immunotech (Beijing) Biotechnology Co., Ltd.·Phase 1·NCT06978647·12 enrolled

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT06056921·24 enrolled

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Recruiting·RRenJi Hospital·Phase 1·NCT06249438·30 enrolled

An Exploratory Clinical Study of CD19 CAR NK Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Recruiting·—·Phase 1·NCT06464679·72 enrolled

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Recruiting·PPersonGen BioTherapeutics (Suzhou) Co., Ltd.·N/A·NCT06361745·10 enrolled

A Clinical Study of CD19 CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases

Recruiting·YYANRU WANG·Phase 1·NCT06318533·15 enrolled

Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases

Recruiting·NNanjing Bioheng Biotech Co., Ltd.·Phase 1·NCT06775912·18 enrolled

Clinical Study of AFN50 Injection in the Autoimmune Diseases

Recruiting·AAlphaNa Bioscience Company Limited·Phase 1·NCT07408336·18 enrolled

Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients

Recruiting·HHospital Universitario Araba·N/A·NCT07249060·300 enrolled

Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases

Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1·NCT07283315·12 enrolled

Safety Study of CC312 in Autoimmune Disease Patients

Recruiting·CCytoCares Inc·Phase 1·NCT06888960·18 enrolled

GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases

Recruiting·GGrit Biotechnology·Phase 1·NCT07122076·10 enrolled

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases

Recruiting·—·Phase 1·NCT06980597·44 enrolled

Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases

Recruiting·RRenJi Hospital·Phase 1·NCT06316076·48 enrolled

Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)